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Megakaryoblastic leukemia 1 (MKL1) deficiency is one of the most recently discovered
primary immunodeficiencies (PIDs) caused by cytoskeletal abnormalities. These
immunological “actinopathies” primarily affect hematopoietic cells, resulting in defects in
both the innate immune system (phagocyte defects) and adaptive immune system (T-cell
and B-cell defects). MKL1 is a transcriptional coactivator that operates together with
serum response factor (SRF) to regulate gene transcription. The MKL/SRF pathway has
been originally described to have important functions in actin regulation in cells. Recent
results indicate that MKL1 also has very important roles in immune cells, and that MKL1
deficiency results in an immunodeficiency affecting the migration and function of primarily
myeloid cells such as neutrophils. Interestingly, several actinopathies are caused by
mutations in genes which are recognized MKL(1/2)-dependent SRF-target genes, namely
ACTB, WIPF1, WDR1, and MSN. Here we summarize these and related (ARPC1B)
actinopathies and their effects on immune cell function, especially focusing on their effects
on leukocyte adhesion and migration. Furthermore, we summarize recent therapeutic
efforts targeting the MKL/SRF pathway in disease.
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Leukocytes constantly traffic between different compartments in the body, and need to be able to
employ different types of adhesion and migration modes in different types of environments. Briefly,
leukocytes adhere to endothelial cells under shear flow conditions using adhesion receptors such as
selectins, integrins, and intercellular adhesion molecules, utilize 2D migration modes on theorg February 2021 | Volume 12 | Article 6154771
Sprenkeler et al. MKL/SRF in Leukocyte Traffickingendothelial cell layer, and migrate in complex tissue
environments utilizing 3D migration. Whereas 2D migration is
strongly dependent on cell adhesion (i.e., ligand binding via
integrins), the 3D amoeboid migration mode of leukocytes such
as dendritic cells is associated with very low adhesion strength
(i.e., integrin-independent) and relies on cytoskeletal
deformation instead (1, 2).
Both during 2D and 3D migration, actin dynamics in
migrating cells is complex and regulated by both positive and
negative regulators. Actomyosin contraction at the cell rear end
(uropod) aids in moving the cytoplasm and cell body, while the
actin-related protein (ARP) 2/3 complex is an important
mediator of actin polymerization at the leading edge (1). The
small GTPases Rac and Cdc42 localize to the leading edge and
regulate actin polymerization (2). In contrast, RhoA localizes to
the uropod where it regulates actin cables (through the formin
mDia) and actomyosin contractility (2). Proteins binding to G-
actin, such as ADF/cofilin, and proteins severing and capping
actin filaments, such as gelsolin, are also important factors
regulating actin dynamics in migrating cells (3).
Primary immunodeficiencies (PIDs) are rare genetic disorders
of the immune system, and lead to immune deficiencies of various
severity. By studying primary immunodeficiencies, much has been
learned about the molecular basis of immune system function,
including leukocyte trafficking. In a classical example, Wiskott-
Aldrich syndrome is causedbydefects in theWASprotein (WASP),
whichplays essential roles in the regulationof the actin cytoskeleton
upon cell activation. Consequently, WASP deficiency leads to
fundamental defects of the immune system, including leukocyte
migration, aswell as aplatelet defectwithbleeding tendencybecause
of reduced platelet counts (4).
Leukocyte adhesion deficiency type I-II and -III in turn are
caused by defects in beta2-integrins, selectins, and kindlin-3,
respectively, and result in severe defects in leukocyte (especially
neutrophil) trafficking into sites of inflammation, as well as specific
defects in adaptive immunity (5). Notably, all abovementioned
defects (apart from LAD-II, which is a metabolic disorder which
also affects leukocytes and neutrophil extravasation) represent
typical hematopoietic disorders. This is explained by the lack of
protein expression outside of the hematopoietic system and/or lack
of redundancy in activity by homologous proteins that may
substitute for the protein that is lacking or dysfunctional in
activity. The selective expression of these proteins within the
hematopoietic system also explains that curative treatment
currently (still) consists of bone marrow transplantation.
Megakaryoblastic leukemia 1 (MKL1) deficiency is one of the
most recently identified primary immunodeficiencies that causes
a rare defect in actin-dependent processes, including leukocyte
adhesion and migration. Here, we review what is known about
MKL1 deficiency and other MKL/SRF (serum response factor)-
related actin-based primary immunodeficiencies. In this review,
we will focus on the proteins involved in this major pathway,
their roles in immune cell migration and effector functions, and
discuss potential lessons to be learned from these diseases and
new opportunities with regards to therapeutic targeting of
this pathway.Frontiers in Immunology | www.frontiersin.org 2THE MKL1/SRF PATHWAY
MKL1, also called MRTF-A (myocardin-related transcription
factor-A) or MAL (megakaryocytic acute leukemia), is a
transcriptional co-regulator expressed in many cell types. It has
long been known to have important roles in regulating actin and
other cytoskeleton genes in many types of cells, together with the
transcription factor SRF. There are two isoforms of MKL, MKL1,
and MKL2, which have similar roles in cells. However, they also
have non-redundant roles, as MKL2 knockout mice are embryonic
lethal (6), while MKL1 knockout mice have a milder phenotype.
MKL1 knockout mice show partial embryonic lethality, abnormal
mammary gland function and reduced platelet count (7).
MKL1 is an interesting transcriptional coactivator,which is itself
regulated by actin cytoskeletal dynamics (8). MKL1 is normally
found in the cytoplasm, where it is bound to G-actin, and therefore
excluded from the nucleus, which means it cannot regulate gene
transcription. When cells receive an activating stimulus, such as
serumstimulation, chemokine stimulationorother types of stimuli,
RhoA is activated, leading to actin polymerization into F-actin.As a
consequence, MKL1 is released from G-actin and transported into
the nucleus (Figure 1). There, it encounters the transcription factor
SRF and together the complex initiates gene transcription. In fact,
SRF recruits two families of coactivators, the MKLs and the TCFs
(ternary complex factors), to couple gene transcription to growth
factor signaling. The MKL/SRF complex is involved in regulating
cytoskeletal genes, such as actin, in many types of cells, including
leukocytes, thereby influencing actin-dependent processes in cells
(Figure 1). In macrophages, the SRF pathway indeed regulates the
expression of cytoskeletal genes (9). In B cells, however, deletion of
SRF also led to decreased expression of IgM, CXCR4 and CD19
(10). The specific role of MKL1 in immune cells is less explored. In
human MKL1-deficient neutrophils, many adhesion and actin
regulators were downregulated, including CASS4, ALCAM, MYL9
(11); proteomic studies further identified WDR and actin itself.
MKL1 also regulated expression of genes involved in interferon
signaling, such as STAT1 and several IFIT genes, but MKL1
deficiency also resulted in the upregulation of several genes (11).
We have recently shown that in murine dendritic cells, MKL1
deletion did not only impact expression of cytoskeletal genes and
genes of cytoskeletal regulators (Fgr, Hck, Stmn1, Ckap2l, Anln,
Tpm2, Tubb5), but also genes encoding for proteins involved in
many other cellular pathways, such as lipid metabolism (12).
Therefore, the effect of MKL1 on gene expression in immune cells
appears to be cell type-specific.However, it is clear thatmanyMKL/
SRF-target genes in leukocytes, as in other cell types, are actin and
actin regulators, for exampleACTB,WIPF1,WDR1, andMSN (13),
which regulate actin cytoskeletal dynamics, and therefore affect
actin-dependent processes in cells (Figures 1 and 2).MKL1 DEFICIENCY
Interestingly, patients with MKL1 mutations have recently been
reported.Thefirst patientwithahomozygousnonsensemutation in
MKL1 was reported in 2015 (14), while two more cases (siblings)February 2021 | Volume 12 | Article 615477
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pneumoniaat an early age, the secondoneunderwentapre-emptive
bone marrow transplant. MKL1 mutations result in primary
immunodeficiency, with increased susceptibility to bacterial
infections (Pseudomonas pneumonia). Lymphocyte counts and
immunoglobulin levels were normal and no major defect in T- or
B-cell function have been reported in these patients (14). Also no
major platelet dysfunction has been reported (11, 14). Neutrophil
numbers were also normal or elevated because of the concomitant
infection. Phagocytosis in patient neutrophils has been reported
both as normal – even of larger particles by neutrophils and
macrophages (11) – and abnormal (14), while neutrophil reactive
oxygen species (ROS) release and bacterial killing have been
reported as being intact in MKL1 patients (11). Azurophilic
granule release was found to be increased by MKL1-deficient
neutrophils under suboptimal stimulation (11).ROLE OF MKL/SRF SIGNALING IN
LEUKOCYTE ADHESION AND MIGRATION
MKL1 deficiency in humans results in a severe migration defect
of neutrophils (reduced chemotaxis towards chemotactic agentsFrontiers in Immunology | www.frontiersin.org 3such as formyl-methionyl-leucyl phenylalanine (fMLF) and
complement component 5a (C5a) (11, 14). Also spreading of
both neutrophils and dendritic cells was reduced (11, 14).
Interestingly, in neutrophils, firm adhesion, and transendothelial
migration under shear flow conditions were severely affected,
although cell adhesion under static conditions was not reduced
(11). Total actin and F-actin levels in neutrophils were reduced
(11, 14). Analysis of protein expression levels by high-resolution
label-free quantitative mass spectrometry showed that indeed
actin and actin regulators (WDR1, ARHGAP9, PFN1) were
downregulated in MKL1-deficient neutrophils (11). The
dramatic effect of the MKL1 mutation on neutrophil phenotype
may be explained by the fact that these cells do not express MKL2,
which may compensate for the lack of MKL1 in other cell types,
such as fibroblasts. Indeed, primary fibroblasts with MKL1
deficiency display normal migration (11).
The role of MKL1 in dendritic cell adhesion and migration
has also been investigated. Interestingly, the MKL1/SRF pathway
is downstream of beta2-integrins and beta2-integrin-mediated
RhoA activation and F-actin polymerization in murine
leukocytes (12). 3D migration of MKL1 knockout dendritic
cells in response to CCL19 was normal, while (static) adhesion
to integrin ligands was slightly reduced. Integrins function asFIGURE 1 | Schematic depicting the molecular regulation of MKL1 in cells. In resting cells, MKL1 is sequestered in the cytoplasm due to binding to G-actin through
its RPEL motifs. Upon cell activation through various stimuli, including serum, chemokines and integrins, Rho GTPases are activated, leading to F-actin
polymerization. This releases MKL1, allowing it to translocate into the nucleus where it can activate gene transcription together with SRF. Some of the cytoskeletal
target genes are shown here; for additional details, see text. Cytoskeletal target genes impact on the actin cytoskeleton in cells, leading to changes in processes
such as cell adhesion and motility.February 2021 | Volume 12 | Article 615477
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the plasma membrane. In MKL1 knockout dendritic cells,
integrin-mediated traction forces were reduced. Dendritic cells
express both MKL1 and MKL2, which presumably underlies the
fact that the adhesion/migration defect of MKL1 knockout
dendritic cells was not as severe as in (human) neutrophils,
which only express the one isoform.
MKL regulates transcription through interactions with SRF,
which has been previously implicated in cell adhesion and
migration in immune cells [reviewed in (15)]. SRF-deficient
murine macrophages display reduced spreading, migration,
and phagocytosis (9). In neutrophils, SRF plays an important
role in cell trafficking in vitro and in vivo. SRF-deficient murine
neutrophils failed to traffic into sites of inflammation in vivo, and
displayed reduced binding to integrin ligands, and cell migration
in vitro (16). Several actin regulators were downregulated in SRFFrontiers in Immunology | www.frontiersin.org 4knockout neutrophils, including Actb. Other SRF targets found
to be downregulated also in murine MKL1 knockout dendritic
cells include Lima1, Actg1, Cnn2, Tpm4, and Wdr1 (12).
MKL1 (and presumably MKL1/SRF-dependent gene
transcription of genes encoding cytoskeletal elements and
additional proteins involved in signaling, etc) therefore appears
to be most important for integrin-mediated cell adhesion under
shear flow conditions, where cells have to withstand substantial
mechanical forces to resist shear forces in blood vessels. In
addition, its role in integrin-mediated traction force generation
further implies that MKL1-regulated gene transcription is
important for integrin mechanoreceptor function. However,
certain other actin-dependent functions appear to function also
without MKL1-signaling (ROS release, bacterial killing) and
seem intact even in the presence of a strongly reduced G-actin
level. It is possible that major actin polymerization is only requiredA
B
C
FIGURE 2 | Comparison of gene expression profiles for MKL1-deficient leukocytes (human and murine cells) (A) Differentially expressed genes (both up- and
downregulated) in MKL1-deficient cells. There were 367 genes in common between them. The second and third Venn diagrams illustrate differentially expressed
genes according to expression profile, i.e., upregulated and downregulated separately. There were 65 common downregulated genes and 109 upregulated genes
between human and mouse MKL1 deficient cells. The mouse genes were converted to humans by Ensembl’s BioMart package and then compared to the human
genes. The Venn diagrams were created using venn.diagram package in R. (B, C) Pathway enrichment analysis using downregulated (B) and upregulated
(C) common genes between human and mouse MKL1-deficient cells. This analysis was performed using Metascape.February 2021 | Volume 12 | Article 615477
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motility, whereas other actin-dependent activities such phagocytosis
and (intraphagosomal) degranulation for the following killing process
of the engulfedmicrobial particles may be less dependent on complex
actin responses. In addition, although there are molecular similarities
between the integrin/cytoskeletal processes involved in cell migration
and phagocytosis, there are also differences [lack of myosin/
contractility in phagocytosis, for example (17)] that may explain
the differential dependence on MKL1/SRF of these processes.
Together, these human and murine data point towards an
important role for MKL/SRF signaling for regulating myeloid
immune cell integrin-mediated adhesion and migration in vivo,
especially affecting neutrophils. Furthermore, mechanistically
MKL1/SRF is probably involved in regulating neutrophil
adhesion and migration through regulation of gene
transcription of actin and actin-related factors/or other factors
that regulate cell adhesion and migration.ACTIN-RELATED PRIMARY
IMMUNODEFICIENCIES INVOLVING MKL/
SRF-TARGET GENES
Interestingly, several primary immunodeficiencies caused by
cytoskeletal abnormalities [“actinopathies” (18–20)] are caused
by mutations in genes which are recognized MKL(1/2)-
dependent SRF-target genes, namely ACTB, WIPF1, WDR1,
and MSN (13). Here, we summarize these actinopathies and
their effect on immune cell function, in an attempt to dissect
which MKL/SRF target genes may be important for leukocyte
adhesion and trafficking.
Cytoplasmic Beta-Actin
Actin is one of the major targets of the MKL/SRF transcription
axis (13) and, as observed in MKL1 deficiency (11, 14) important
for homeostatic levels of actin. Actin has six isoforms, one of
which is cytoplasmic beta-actin (encoded by ACTB) (21).
Although loss-of-function mutations in ACTB have not been
reported to cause a PID, it has been described that patients suffer
from recurrent infections, which may imply an influence of these
mutations on the immune system (22).
One report on immune cell function in a patient with a
missense mutation in ACTB identified reduced chemotaxis and
decreased ROS production of neutrophils (23). This mutation led
to the expression of both normal and mutated cytoplasmic beta-
actin in patient cells, including fibroblasts, leukocytes, Epstein–
Barr virus-transformed B-cells, and platelets (23). Further
investigation revealed that this mutated beta-actin had a slower
polymerization rate than normal actin (24). More recently, a lack
of beta-actin in mouse embryonic fibroblasts was shown to
downregulate interferon-stimulated genes due to instability of
the transcription factor interferon regulatory factor 3, thereby
impairing the antiviral response (25). Likewise, SRF has been
previously shown to be important for type I interferon signaling
by induction of several interferon-stimulated genes (26).Frontiers in Immunology | www.frontiersin.org 5Wiskott-Aldrich Syndrome Protein-
Interacting Protein
Actin polymerization, i.e., the assembly of G-actin into F-actin, is
mediated by the Wiskott-Aldrich syndrome protein (WASP), as
it activates the actin-related proteins-2/3 (ARP2/3) complex.
This complex, consisting of seven subunits, is an actin
nucleator which initiates the branching of actin filaments (27).
The Wiskott-Aldrich syndrome protein-interacting protein
(WIP) interacts with WASP, thereby stabilizing its inactive
state. When WASP gets activated, WIP is phosphorylated and
dissociates from WASP (28, 29). The human gene encoding for
WIP, WIPF1, has been identified to be a MKL-dependent SRF-
target gene (13).
Only a handful of patients with WIP deficiency, caused by
autosomal recessive mutations in WIPF1, have been identified
thus far (30–32). As WIP regulates the stability and localization
of WASP (33), loss of WIP will also lead to absence of WASP (30,
34). Therefore, patients with WIP deficiency have a similar
clinical phenotype as WAS patients, i.e., recurrent infections,
thrombocytopenia, and eczema (31, 35).
The adaptive immune cells, i.e., T-cells and B-cells, are most
affected in WIP deficiency. Patients suffer from T-cell
lymphopenia, where CD8+ T-cells are more affected (35).
Functionally, T-cells showed impaired proliferation, defective
chemotaxis, defective exocytosis, and reduced target killing,
most likely because there is a failure to assemble the
immunological synapse (30, 32). Also, T-cells had an
abnormal morphology, and failed to elongate and assemble a
leading- and trailing edge upon stimulation (32). Natural killer
(NK) cell–mediated cytotoxicity was reported to be reduced
(30), and B-cells showed a chemotaxis defect, which could be
rescued when WIP expression was restored in these cells (32).
No defects in neutrophil function were reported in WIP
patients, and monocyte-derived dendritic cells showed a
normal phenotype (32). As the phenotype is quite different
from that seen in MKL1 deficiency,WIPF1may not be the most
important gene regulating neutrophil trafficking downstream of
MKL/SRF.
WD Repeat-Containing Protein 1
Actin-interacting protein 1 (Aip1), encoded WDR1, is an actin-
binding protein which enhances the disassembly and severing of
actin filaments by cofilin (36, 37).WDR1 is identified as an MKL/
SRF target gene (13), and expression of WDR1 is strongly
reduced in murine cells lacking Srf (38), in murine dendritic
cells lackingMkl1 (12), and on the protein level in neutrophils of
MKL1-deficient patients (11). Mutations in WDR1 have been
reported to cause immunodeficiency (39–41), and WDR1 is
considered to be the main candidate gene to cause the “Lazy
Leukocyte Syndrome”, first described in 1971 (42). Patients with
loss-of-function mutations in WDR1 are reported to suffer from
recurrent infections, mild neutropenia and impaired wound
healing (39), but also a separate syndrome of auto-
inflammation, periodic fever, and thrombocytopenia has been
reported (40, 41).February 2021 | Volume 12 | Article 615477
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monocytes, dendritic cells, and lymphocytes, are defective in
actin depolymerization, resulting in increased F-actin levels (39–
41). About 50% of the neutrophils had an altered herniation of
their nuclear lobes, which co-localized with increased F-actin
staining (39, 40). Neutrophils had a severe chemotaxis defect and
showed abnormal spreading on glass, while Staphylococcal
aureus killing and phagocytosis of opsonized Escherichia coli
were reported to be normal. ROS production was found both
normal and enhanced in WDR1-deficient neutrophils (39–41).
Monocytes showed increased spreading over fibronectin, and
CD14+ peripheral blood mononuclear cells showed an increased
caspase-1 activation, which corresponds with auto-inflammation
(40, 41).
Furthermore, defects in the adaptive immune system were
observed. T-cells had an increased spreading capacity and
mildly impaired proliferation, but normal T-cell receptor
internalization, normal migration, and normal killing of
target cells by CD8+ T-cells (40). B-cells showed increased
apoptosis on B-cell receptor/Toll-like receptor stimulation
and abnormal spreading, but normal migration. Also,
patients suffered from peripheral B-cell lymphopenia and
there was a lack of switched memory B-cells, reduced clonal
diversity and paucity of B-cell progenitors in the bone
marrow (40).
Moesin
Moesin (encoded by MSN) is a member of the ezrin, radixin,
moesin (ERM) protein family, which link cortical actin
filaments to the plasma membrane and membrane receptors.
ERM proteins are important for structural stability and the
integrity of the cell cortex (43). MSN is recognized to be a
MKL-dependent SRF-target gene (13). As MSN is located on
the X chromosome, the immunodeficiency was termed X-
linked moesin associated immunodeficiency (44). Patients
suffer from recurrent bacterial- and viral infections,
persistent eczema and lymphopenia, as well as fluctuating
neutropenia (44–46).
MSN-deficient T-cells showed impaired proliferation,
impaired chemotaxis, and increased adhesion to vascular cell
adhesion molecule 1 (44). While no functional analysis was done
on neutrophils or monocytes from these patients, neutrophils
from male moesin-deficient mice (Msn -/Y) did display elevated
rolling velocity in inflamed blood vessels, indicating that moesin
has an important role in slow leukocyte rolling and subsequent
trans-endothelial migration (47). Also, moesin-deficient mice
showed a reduced neutrophil microbial killing ability towards
Pseudomonas aeruginosa and reduced neutrophil-mediated
vascular inflammation, while neutrophil adhesion was not
affected (48).
Actin-Related Proteins 2/3 Complex
Subunit 1B
The ARP2/3 complex, consisting of seven subunits, plays an
essential role in the formation of branched actin networks by
nucleating a daughter filament to the side of a pre-existing actinFrontiers in Immunology | www.frontiersin.org 6filament (27). These branched actin networks are especially of
importance for generating a protrusive force that aids in cellular
adhesion and motility (49). Almost all subunits of the ARP2/3
complex have been recognized to be MKL/SRF-target genes
[ARP2, ARP3, ARP2/3 complex subunit 2 (ARPC2), ARPC4,
and ARPC5] (13), suggesting that MKL1/SRF is involved in actin
branching by regulating transcription of ARP2/3 complex family
members. ARPC1 is present in two isoforms in humans,
ARPC1A and ARPC1B, the latter being the dominant form in
hematopoietic cells (50, 51). Although it is not (yet) identified as
a MKL/SRF-target gene, patients with ARPC1B deficiency have a
very similar neutrophil phenotype compared to MKL1-
deficient patients.
Patients with ARPC1B deficiency suffer from a combined
immunodeficiency including a neutrophil defect, resulting
clinically in bacterial- and viral infections, bleeding tendency,
eczema, allergy, and vasculitis (50–55). Similar to MKL1
deficiency, neutrophils have a severe migration defect due to
an actin polymerization defect. Also, ROS production and the
phagocytosis and killing of bacteria were found to be intact, and
azurophilic granule release was increased under suboptimal
stimulation (50).
Although no major defects in T- or B-cell function have been
reported in MKL1 deficiency, ARPC1B deficiency does result in
lymphocytes defects, including defective migration and
proliferation, defective immunological synapse assembly by
T-cells (53, 55), impaired regulatory T-cell suppressor activity
and impaired NK-cell degranulation (52). Primary fibroblasts
showed normal migration, most likely due to expression of
ARPC1A in these cells (similar to possible MKL2 compensation
in MKL1 deficiency) (50).
Thus, MKL1-deficient neutrophils have an almost identical
phenotype as ARPC1B-deficient neutrophils, which could be
explained by the involvement of MKL/SRF in transcription of
ARP2/3 complex family members. However, ARPC1B
deficiency also affects lymphocytes, which has not been
observed in MKL1 deficiency. A possible explanation might
be redundancy of MKL2 in lymphocytes, which express low
levels of this isoform.
In conclusion, analysis of primary immunodeficiencies
involving MKL/SRF targets and putative targets (Table 1)
implicate ARP-subunits as possible targets downstream of
MKL/SRF that could be involved in regulating leukocyte
adhesion and migration in vivo.TARGETING OF MKL/SRF IN IMMUNE
CELL-MEDIATED INFLAMMATION—
NEW POSSIBILITIES?
MKL/SRF signaling and MKL/SRF regulated gene expression
of actin-related factors are important in leukocyte adhesion
and migration, as shown by the actin-related primary
immunodeficiencies described above. Interestingly, genetic
syndromes also exist where actin dynamics is upregulated,
eg X-linked neutropenia. In this disease, neutrophil levels inFebruary 2021 | Volume 12 | Article 615477
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into tissues. X-linked neutropenia is caused by gain-of-
function mutations in WASP, leading to increased actin
dynamics, and, as a consequence, to upregulation of actin-
dependent neutrophil adhesion, migration, and recruitment
into tissues (57).
As MKL/SRF signaling and downstream targets of this
pathway are clearly associated with leukocyte migration,
targeting this pathway in inflammatory diseases where
leukocyte migration into tissues is upregulated may offer a new
therapeutic strategy. MKL/SRF signaling is important in many
cell types and tissues, and is also implicated in disease in different
settings. Indeed, the MKL/SRF pathway has already been
targeted in a number of different diseases, including several
with an immune/inflammatory cell component, such as fibrosis
and corneal wound healing. Interestingly, MKL/SRF inhibitors
have been used to treat fibrosis in lung, skin, colon, liver, joints,
and the eye (both the external cornea and the internal subretina)
(Table 2). The target for these therapeutic approaches are
myofibroblasts and the excess extracellular matrix (ECM)
production by these cells, as MKL1 has been found to be
important for myofibroblast differentiation (74). However, in
scleroderma/systemic sclerosis patient skin samples, a disease
associated with internal organ stiffening due to fibrosis, nuclear
MKL1 has also been found in infiltrating macrophages (65),
where it has been linked to proinflammatory gene expression
(75, 76), indicating that also macrophages could be a target cell
type for SRF inhibition in fibrosis.Frontiers in Immunology | www.frontiersin.org 7Targeting the MKL/SRF pathway to improve corneal wound
healing has emerged as an attractive strategy. The cornea is a
transparent endothelial cell layer in the eye and its thinning as
well as replacement with connective and corneal stroma is
associated with blindness. In the cornea, stromal cells produce
cytokines like interleukin-1 (IL-1) and transforming growth
factor-b (TGF-b) to induce inflammatory and degradative
processes or to induce ECM deposition (77). TGF-b1 activates
the MKL/SRF pathway (67, 78), indicating MKL/SRF could
play a role in corneal wound healing (79). Indeed, eye
drops supplemented with the inhibitor Y-27632 to inhibit
Rho Associated Kinase (ROCK) upstream of MKL/SRF, have
been used to improve corneal endothelial wound healing in
vivo (80).SUMMARY AND FUTURE PROSPECTS
MKL1 deficiency is one of the most recently identified
primary immunodeficiencies and is associated with globally
impaired actin regulation, defective cell adhesion and
abnormal trafficking of myeloid leukocytes. Studies in both
mouse and man have provided novel insights into its complex
role in immune cell migration and function in the context
of infections. The main cell types affected by MKL1
deficiency and MKL/SRF signaling are neutrophils and
macrophages. Neutrophils are involved in a wide variety of
inflammatory processes including acute organ injury, cysticTABLE 1 | List of MKL/SRF-related actinopathies with corresponding protein function, clinical symptoms, and reported functionally affected hematopoietic cells in these patients.
Actinopathy
(gene)
Protein function MKL/SRF target
gene






Coactivator of transcription factor SRF,
thereby involved in regulating
cytoskeletal gene transcription






Non-muscle actin; one of the six
isoforms of actin
Yes Recurrent infections Neutrophils (23)
WIP deficiency
(WIPF1)
Interacts with WASP, thereby
stabilizing its inactive state







Actin-binding protein, enhances the
disassembly and severing of actin
filaments by cofilin
Yes Recurrent infections, mild neutropenia,









Member of the ERM protein family;
links cortical actin filaments to the
plasma membrane and membrane
receptors






Subunit of the ARP2/3 complex,
thereby involved in branching of actin
filaments




Recurrent bacterial- and viral infections,





(50–55)February 2021 | Volume 12 | AA more elaborate table of immunological actinopathies, including those caused by mutations in non-MKL/SRF target genes, can be found in the review by Sprenkeler et al.
(56). ARPC1B, actin-related protein complex 2/3 subunit 1B; ARP2/3 complex, actin-related protein complex 2/3; ERM, ezrin/radixin/moesin; MKL1, megakaryoblastic
leukemia 1; NK-cells, natural killer cells; SRF, serum response factor; WASP, Wiskott-Aldrich syndrome protein; WDR1, WD repeat-containing domain 1; WIP, WASP-
interacting protein.rticle 615477
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autoimmunity (such as rheumatoid arthritis). It is tempting
to speculate that MKL/SRF, which is already being targeted in
several diseases (Table 2) could also be used to reduce
neutrophil and macrophage trafficking in these and other
inflammatory disorders.Frontiers in Immunology | www.frontiersin.org 8AUTHOR CONTRIBUTIONS
ES, CG, TK, and SF wrote the manuscript on behalf of the
LADOMICS consortium. IF analyzed bioinformatics data and
made Figure 2. All authors contributed to the article and
approved the submitted version.TABLE 2 | MKL/SRF targeting in disease.








Daily administration of 100 mg/kg CCG-222740
reduced and delayed subconjunctival scarring after
glaucoma filtration surgery and improved surgery
success by 67%. CCG-203971 delayed slightly less
subconjunctival scarring and improved surgery
success by 33% compared to a control. Inhibitors
decreased cellularity and a-smooth muscle actin (a-
SMA expression
Fibroblast mediated collagen contraction assay
(inhibitor tests); in vivo scar tissue formation
(subconjunctival scarring after glaucoma
filtration surgery) model in rabbits
(58)
Subretinal fibrosis CCG-1423 Inhibited cell migration; inhibition of TGF-b induced
MKL1 shuttling, Paxilin and pro-MMP-2 expression;
injection into vitreous cavity inhibited fibrosis
development
Human retinal pigment epithelial cells (RPE-1
cells);
murine in vivo CNV model
(59)
Dermal fibrosis CCG-203971 Inhibited expression of connective tissue growth
factor (CTGF), a-SMA, and collagen 1 (COL1A2) in
fibroblasts. In mice CCG-203971 prevented
bleomycin-induced skin thickening and collagen
deposition
Systemic sclerosis fibroblasts, Bleomycin-
Induced Injury Model
(60)
Dermal scarring Fasudil (ROCK inhibitor) Inhibited fibroblast contractility, and myofibroblast
formation in vitro; inhibited wound contraction in vivo
Wistar-han rats (61)
Colon fibrosis CCG-1423, CCG-
100602 and CCG-
203971
Repressed matrix-stiffness and TGF-b mediated
fibrogenesis
In vitro models using human colonic fibroblast
CCD-18co cells (CRL-1459, derived from a
female donor)
(62)
Liver fibrosis CCG-1423 Alleviated c-Abl inhibition. c-Abl activation is
associated with cellular fibrogenesis
Primary hepatic stellate cells, Immortalized






Suppressed mRNA levels of a-SMA and type I
collagen
Fibroblast-like synoviocytes cell line (64)
Scleroderma/
systemic sclerosis
(lung and skin in
study)





In vitro: inhibited MKL1 shuttling, blocked
myofibroblast differentiation, inhibited TGF-b1-induced
expression of fibronectin, X-linked inhibitor of
apoptosis, and plasminogen activator inhibitor-1. In
vivo: reduced lung collagen content, decreased
alveolar plasminogen activator inhibitor-1 and
promoted myofibroblast apoptosis
Adult primary human lung and primary human
fetal lung fibroblast cell lines (CCL-210 IMR-90)
Murine models of fibrosis induced by:
•bleomycin
•targeted type II alveolar epithelial injury
(66)





Inhibition of SRF in a disease mouse model
increased survival from 98 days (ctrl) to 116
Murine CAP2 KO in vivo model (68)
Vascular proliferative
diseases
CCG-1423 Intraperitoneal treatment with 0.15 mg/kg for 3
weeks inhibited progression of vascular remodeling in
arteries






Reduced the stiffness of reconstituted tissue and
changed LOX gene expression
Primary vascular smooth muscle cells (VSMCs)
isolated from rats used for other experiments in
the study, in vitro reconstituted tissue
(70)
Aortic stiffening CCG-100602 1.5 mg/kg/
day for 2 weeks delivered
by subcutaneous
osmotic minipump
Reduced aortic stiffness and then blood pressure in
SHR but not in WKY rats
Spontaneously hypertensive rats (SHR)
Normotensive Wistar-Kyoto (WKY) rats
(71)
Hypertension Y-27632 (Rock inhibitor),
CCG-100602
Reduced aorta wall stiffness and blood pressure in
vivo
In vitro VSMC models and SHR and WKY rats (72)
Pulmonary Arterial
Hypertension
CCG-1423 Attenuated pulmonary arterial hypertension and lung
vascular remodeling
Sugen/hypoxia rats (73)February 2021 | Volume 12 | ATargeted diseases, inhibitors used, and the model systems used are described in this table.rticle 615477
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